In a new study, researchers found that a commonly prescribed anti-inflammatory may increase the risk of diabetes after just one week of treatment.
Healthy men who were given doses of the drug were compared to those used to treat inflammatory disorders.
They had changes in markers of blood sugar metabolism associated with an increased risk of developing diabetes.
The findings highlight the potential long-term health implications for people regularly taking these drugs and that medical professionals may need to consider and monitor the potential side-effects, to avoid future debilitating conditions.
The research was conducted by a team from the Sapienza University of Rome and the University of Oxford.
Glucocorticoids (GCs) are one of the most commonly prescribed anti-inflammatories for conditions such as arthritis, asthma, allergies, and adrenal insufficiency.
GC treatment at high doses for a long duration is known to be associated with metabolic side-effects that may increase the risk of diabetes and obesity but there are currently no studies examining the short-term effects of GCs at the more regularly prescribed, lower doses.
As 2-3% of the UK population take GCs for conditions of varying severity, it is important to investigate whether these metabolic side-effects occur in a lower dose, short-term therapy.
The team measured markers of metabolism in healthy men given commonly prescribed doses (10 and 15mg) of GCs (prednisolone) after just one week of treatment.
Although commonly checked clinical and biochemical parameters such as fasting blood sugar levels, weight and general health were unaffected, changes in metabolic markers indicated that their blood sugar regulation was impaired.
This is the first study to examine the very short-term metabolic effects of commonly prescribed doses of glucocorticoids on healthy men and indicates, that even at these lower doses, glucose metabolism is impaired, suggesting an increased risk of diabetes with continued treatment.
These novel findings not only highlight the importance of determining the best GC dose that balances effectiveness with potentially negative metabolic effects, but also that medical professionals should be more aware of these risks and may need to monitor them in patients both on short and longer-term therapy.
One author of the study is Dr. Riccardo Pofi.
The study was presented at The Society for Endocrinology Annual Conference.
Copyright © 2019 Knowridge Science Report. All rights reserved.
